Tesamorelin is a synthetic analog of growth-hormone-releasing factor (GRF). Unlike ipamorelin, which is studied as a ghrelin-receptor agonist, tesamorelin acts through the GRF receptor pathway. The compound has both a research literature and a specific FDA-approved pharmaceutical context, which must be kept separate from third-party RUO materials.
What is tesamorelin?
Tesamorelin is based on the human GRF sequence with a modification designed to alter stability. The defined sequence and chemical form distinguish it from native GRF, CJC analogs, growth hormone itself, and ghrelin-receptor secretagogues. Reference identifiers describe the selected compound record, not a commercial batch.
LiveWire maintains separate 10 mg and 20 mg listings. Their strength URLs support procurement comparison, while this article owns informational research intent.
GRF pathway context
GRF receptor activation in the pituitary is associated with growth-hormone release and downstream endocrine effects. Research evaluates those pathways under defined experimental or clinical conditions. A mechanistic description does not mean that every downstream outcome is beneficial, predictable, or appropriate outside an approved context.
Comparisons with ipamorelin or CJC-1295 require attention to receptor target, molecular design, duration, study model, and formulation. “Growth hormone peptide” is too broad to describe these differences accurately.
Clinical evidence
Clinical trials evaluated tesamorelin in HIV-associated lipodystrophy. Spooner and Olin reviewed efficacy and safety data available after approval. Clinical findings belong to the studied pharmaceutical product, population, endpoints, duration, and monitoring. They should not be converted into general weight-loss or body-composition recommendations.
Approved-product literature can inform the compound’s documented pharmacology and risks. It does not validate an unrelated research vial or create an off-label consumer guide.
Specific approved drug context
FDA labeling for EGRIFTA identifies tesamorelin as a GRF analog indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The labeling also states that it is not indicated for weight-loss management and notes limitations of evidence. Initial U.S. approval was in 2010.
That approval applies to the regulated EGRIFTA product, sponsor, formulation, manufacturing controls, and labeling. This article does not reproduce dosage or administration directions because LiveWire does not supply the approved drug or provide medical guidance.
RUO product separation
The LiveWire tesamorelin listings are research-use-only materials. They are not EGRIFTA and do not inherit its approval, indication, quality system, clinical evidence, or instructions. Product-specific identity and batch documentation must be evaluated independently.
This distinction is especially important for search intent: the article explains evidence and regulatory context, while the product pages provide SKU, labeled amount, price, and documentation status for qualified research procurement.
Related LiveWire resources
The Tesamorelin Research Database record provides structured reference facts. Separate procurement pages cover Tesamorelin 10 mg and Tesamorelin 20 mg.
Reading the approved label as a source
An FDA label is authoritative for the approved product’s indication, limitations, contraindications, warnings, and use conditions. It is not a scientific review of every experimental hypothesis about the molecule. For SEO content, the label should support the narrow regulatory statement while peer-reviewed trials and reviews support study-specific scientific context.
The EGRIFTA label’s limitation that it is not indicated for weight-loss management is particularly important because search content can otherwise collapse HIV-associated lipodystrophy research into general weight-loss marketing. LiveWire avoids that target and does not use the pharmaceutical brand as a commercial keyword for its RUO materials.
Why two product strengths remain separate
The 10 mg and 20 mg listings have distinct labeled amounts, SKUs, prices, inventory, and canonical URLs. The research article should not compete for either procurement query. It links to both only in a resource section, while its primary intent is the compound’s research and regulatory context.
Any batch report must connect to the exact product and lot. A report for one strength or inventory batch should not be reused for another merely because the underlying named compound is tesamorelin.
Add LiveWire as a preferred source
Use Google’s standard Preferred Sources control to make LiveWire Peptides easier to find in supported Google experiences.
References
- Bailly-Chouriberry L, Cormant F, Garcia P, et al.. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. The AAPS Journal. 2023. PMID 36949371 Peer-reviewed primary/methods literature
- National Center for Biotechnology Information. PubChem PUG REST Documentation. NIH PubChem. 2026 Authoritative scientific database documentation
- Spooner LM, Olin JL. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. The Annals of Pharmacotherapy. 2012. PMID 22298602 Peer-reviewed review
- U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) Highlights of Prescribing Information. Drugs@FDA. 2019. NDA 022505 Authoritative regulatory labeling record